ProMIS Neurosciences EV / EBITDA
Was ist das EV / EBITDA von ProMIS Neurosciences?
EV / EBITDA von ProMIS Neurosciences, Inc. ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf OTC im Vergleich zu ProMIS Neurosciences
Was macht ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Unternehmen mit ev / ebitda ähnlich ProMIS Neurosciences
- Good2 Go4 Corp hat EV / EBITDA von N/A
- 3D Resources hat EV / EBITDA von N/A
- Litian Pictures hat EV / EBITDA von N/A
- Dimerix hat EV / EBITDA von N/A
- Inogen Inc hat EV / EBITDA von N/A
- Taung Gold International hat EV / EBITDA von N/A
- ProMIS Neurosciences hat EV / EBITDA von N/A
- China Youzan hat EV / EBITDA von N/A
- PanAsialum hat EV / EBITDA von N/A
- Damstra Ltd hat EV / EBITDA von N/A
- IDT International hat EV / EBITDA von N/A
- Kalytera Therapeutics hat EV / EBITDA von N/A
- Purepoint Uranium hat EV / EBITDA von N/A